Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)

Prostate

Volumn 72, Issue 8, 2012, Pages 913-924

  Jennbacken, Karin ^a   Welén, Karin ^a   Olsson, Anders ^b   Axelsson, Bengt ^b   Törngren, Marie ^b   Damber, Jan Erik ^a   Leanderson, Tomas ^b,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Active Biotech Research AB   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

angiogenesis; bone metastasis; CXCR4; thrombospondin

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MOLECULAR MARKER; PROTEIN LYSINE 6 OXIDASE; STROMAL CELL DERIVED FACTOR 1; TASQUINIMOD; THROMBOSPONDIN 1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL HYPOXIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SKIN TUMOR; TIBIA; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; QUINOLINES; TREATMENT OUTCOME; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860319412     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21495     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-249.
2. Dalrymple SL, Becker RE, Isaacs JT,. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 2007; 67 (7): 790-797. (Pubitemid 46709447)
3. Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Bjork A, Olsson A, Leanderson T,. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006; 66 (16): 1768-1778. (Pubitemid 44893902)
4. Isaacs JT,. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opin Investig Drugs 2010; 19 (10): 1235-1243.
5. Bratt O, Haggman M, Ahlgren G, Nordle O, Bjork A, Damber JE,. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer 2009; 101 (8): 1233-1240.
6. Pili R, Häggman M, Stadler WM, Gingrich J, Assikis V, Björk A, Nordle Ã, Forsberg G, Carducci MA, Armstrong AJ,. Phase II randomized double blind placebo-controlled study to determine the efficacy of tasquinimod in asymptomatic patients with metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; DOI: 10.1200/JCO.2011.35.6295.
7. Olsson A, Bjork A, Vallon-Christersson J, Isaacs JT, Leanderson T,. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010; 9 (1): 107.
8. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T,. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009; 7 (4): e97.
9. Hiratsuka S, Watanabe A, Aburatani H, Maru Y,. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8 (12): 1369-1375. (Pubitemid 44835111)
10. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, Shibuya M, Akira S, Aburatani H, Maru Y,. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008; 10 (11): 1349-1355.
11. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, Roth J, Gabrilovich DI,. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205 (10): 2235-2249.
12. Dalrymple SL, Becker RE, Zhou H, Deweese TL, Isaacs JT,. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate 2011; DOI: 10.1002/pros.21467.
13. Folkman J,. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285 (21): 1182-1186.
14. Lawler J,. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6 (1): 1-12. (Pubitemid 44133979)
15. Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder JP Jr, Folkman J, Soker S,. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 2003; 63 (23): 8345-8350. (Pubitemid 37549488)
16. Semenza GL,. HIF-1: Using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000; 19 (1-2): 59-65. (Pubitemid 32004693)
17. 2 tension. Proc Natl Acad Sci USA 1995; 92 (12): 5510-5514.
18. Ishikawa T, Nakashiro K, Klosek SK, Goda H, Hara S, Uchida D, Hamakawa H,. Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol Rep 2009; 21 (3): 707-712.
19. Harris AL,. HypoxiaâA key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2 (1): 38-47. (Pubitemid 37328806)
20. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T,. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007; 67 (9): 4157-4163. (Pubitemid 46815061)
21. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW,. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59 (22): 5830-5835.
22. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia AJ,. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15 (1): 35-44.
23. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC,. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10 (8): 858-864. (Pubitemid 39070860)
24. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, Taichman RS,. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20 (2): 318-329.
25. Hernandez L, Smirnova T, Kedrin D, Wyckoff J, Zhu L, Stanley ER, Cox D, Muller WJ, Pollard JW, Van Rooijen N, Segall JE,. The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. Cancer Res 2009; 69 (7): 3221-3227.
26. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G,. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13 (3): 206-220. (Pubitemid 351318372)
27. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V,. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222: 162-179. (Pubitemid 351430364)
28. Ostrand-Rosenberg S, Sinha P,. Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol 2009; 182 (8): 4499-4506.
29. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC,. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6 (4): 409-421. (Pubitemid 39361441)
30. Gustavsson H, Welen K, Damber JE,. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005; 62 (4): 364-373. (Pubitemid 40227488)
31. Jennbacken K, Gustavsson H, Welen K, Vallbo C, Damber JE,. Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate 2006; 66 (15): 1631-1640. (Pubitemid 44646354)
32. Jennbacken K, Gustavsson H, Tesan T, Horn M, Vallbo C, Welen K, Damber JE,. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: An effect influenced by testosterone. Prostate 2009; 69 (11): 1164-1175.
33. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL,. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 2002; 52 (1): 20-33. (Pubitemid 34553189)
34. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP,. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4 (2): 249-264.
35. Welen K, Jennbacken K, Tesan T, Damber JE,. Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts. Prostate Cancer Prostatic Dis 2009; 12 (1): 41-46.
36. Chambers AF, Groom AC, MacDonald IC,. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2 (8): 563-572. (Pubitemid 37328923)
37. Damber JE, Aus G,. Prostate cancer. Lancet 2008; 371 (9625): 1710-1721. (Pubitemid 351671887)
38. Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, Chambers AF, MacDonald IC,. Temporal progression of metastasis in lung: Cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 2000; 60 (9): 2541-2546. (Pubitemid 30262450)
39. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC,. Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153 (3): 865-873. (Pubitemid 28419039)
40. Vukanovic J, Hartley-Asp B, Isaacs JT,. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate 1995; 26 (5): 235-246.
41. Diab A, Michael L, Wahren B, Deng GM, Bjork J, Hedlund G, Zhu J,. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. J Neuroimmunol 1998; 85 (2): 146-154. (Pubitemid 28313499)
42. Moon Y, Bottone FG Jr, McEntee MF, Eling TE,. Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. Mol Cancer Ther 2005; 4 (10): 1551-1558. (Pubitemid 41556438)
43. Volpert OV, Lawler J, Bouck NP,. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci USA 1998; 95 (11): 6343-6348. (Pubitemid 28249014)
44. Mendez O, Zavadil J, Esencay M, Lukyanov Y, Santovasi D, Wang SC, Newcomb EW, Zagzag D,. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer 2010; 9: 133.
45. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A,. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410 (6824): 50-56. (Pubitemid 32225831)
46. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK,. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62 (6): 1832-1837. (Pubitemid 34408510)
47. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA,. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 2009; 4 (9): e6896.
48. Lee Y, Kim SJ, Park HD, Park EH, Huang SM, Jeon SB, Kim JM, Lim DS, Koh SS,. PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression. Oncogene 2010; 29 (1): 56-67.
49. Singh S, Singh UP, Grizzle WE, Lillard JW Jr., CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004; 84 (12): 1666-1676. (Pubitemid 39600573)